Celltrion and LISCure Biosciences to develop unique microbiome treatment for Parkinson’s disease
LISCure Biosciences Inc., a clinical-stage biotech is developing advanced microbiome technology with accurate targets and announced a multi-year strategic R&D collaboration with Celltrion to identify novel microbiome therapy for neurodegenerative diseases like Parkinson’s disease.
– Co-research and co-development of novel microbiome therapeutics.
– Discovery of new candidates to meet high unmet medical needs in
In an agreement, Celltrion and LISCure planned to develop oral Live Biotherapeutic Products (LBPs) for Parkinson’s disease. LISCure will be having research funding and will be able to receive additional payments as the project progresses. LISCure will lead the discovery of unique candidates and Celltrion will be in charge of further clinical and regulatory development.
Parkinson’s disease is a brain-related disorder that can cause uncontrolled movements like shaking, stiff muscles, and difficulty with balance. This disease occurs due to the extremely low level of dopamine and abnormal aggregation of α- synuclein associated with gut dysbiosis; this microbiome-based therapy is proven to be very effective in order to treat Parkinson’s disease. These techniques help in the advancement of brain-target bacterial exosome technology which is used for neurodegenerative disorders like Parkinson’s disease and Alzheimer’s disease. The global market size of Parkinson’s disease treatment was valued at USD 3.5 billion in 2019 and is anticipated to reach USD 11.5 billion in 2029 (CAGR=12.6%). The US Parkinson’s disease market size was USD 1.8 billion in 2019 (market share = 51.5%)